US 9,808,434 B2Granted

Compound for treating cancer and diabetes

AssigneeCity of Hope

InventorsSamuel Rahbar, James L. Figarola, Christopher Lincoln, David Horne, Rachael Mooney, Monika Polewski, George Somlo, Lixin Yang, Sanjay Awasthi, Sharad Singhal, Jyotasana Singhal

Life of this patent

Estimating the term…

Abstract

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Claims16

Dependent claims

A method of treating a cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of 1,3-bis (3,5-dichlorophenyl) urea (COH-SR4), a salt thereof, or stereoisomers thereof, wherein the cancer is selected from the group consisting of melanoma, and lung cancer.

Dependencies are inferred from the claim text.

Facts

Application: 15/173,628Filed 4 Jun 2016 · continuation in part
Priority: 27 Jan 2011
Published: US 2016/0354327 A18 Dec 2016
Granted: 7 Nov 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/17
Amides, e.g. hydroxamic acids: having the group >N—C—N< or >N—C—N<, e.g. urea, thiourea, carmustine
A61K 31/4745
Ortho- or peri-condensed with heterocyclic ring systems: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…
A61K 31/513
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Family

Application61/436,958Us provisional application · filed 27 Jan 2011
PCT/US2012/023034Parent of this continuation · filed 27 Jan 2012
Application13/953,013Parent of this continuation-in-part · filed 29 Jul 2013
US 2016/0354327 A1Pre-grant publication · published 8 Dec 2016
Application13/953,013Parent of this continuation
US 10,029,991 B2Related patent
US 2014/0162996 A1Published application
US 9,808,434 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Facts

Application

15/173,628Filed 4 Jun 2016 · continuation in part

Priority

27 Jan 2011

Published

US 2016/0354327 A18 Dec 2016

Granted

7 Nov 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/17
Amides, e.g. hydroxamic acids: having the group >N—C—N< or >N—C—N<, e.g. urea, thiourea, carmustine
A61K 31/4745
Ortho- or peri-condensed with heterocyclic ring systems: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…
A61K 31/513
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Family

Application61/436,958Us provisional application · filed 27 Jan 2011

PCT/US2012/023034Parent of this continuation · filed 27 Jan 2012

Application13/953,013Parent of this continuation-in-part · filed 29 Jul 2013

US 2016/0354327 A1Pre-grant publication · published 8 Dec 2016

Application13/953,013Parent of this continuation

US 10,029,991 B2Related patent

US 2014/0162996 A1Published application

US 9,808,434 B2This patent

From the US filing history. Foreign family members aren’t listed.